Research progress of phosphatidylinositol 3-kinase inhibitors in relapsed refractory peripheral T-cell lymphoma
10.3760/cma.j.cn101721-20240807-00251
- VernacularTitle:磷脂酰肌醇3-激酶抑制剂在复发难治外周T细胞淋巴瘤中的研究进展
- Author:
Zhijuan PAN
1
;
Yiqun ZHANG
;
Zhiping GUO
Author Information
1. 北京大学第一医院太原医院 太原市中心医院血液科，太原 030006
- Keywords:
Lymphoma, Relapsed refractory;
Phosphatidylinositol 3-kinase;
Peripheral T cells
- From:
Clinical Medicine of China
2024;40(6):422-426
- CountryChina
- Language:Chinese
-
Abstract:
Peripheral T-cell lymphoma (PTCL) is a relatively common subtype of non-Hodgkin lymphomain in China. PTCL is clinically highly aggressive, and it progresses rapidly. The current treatment methods are ineffective and the overall prognosis is poor, especially in patients with relapsed and/or refractory. In recent years, the treatment of phosphatidylinositol 3-kinase (PI3K) inhibitors has developed rapidly, which can effectively improve the prognosis of patients with relapsed and/or refractory PTCL. This article reviews the therapeutic mechanism, effectiveness and safety of PI3K inhibitors in the treatment of relapsed and/or refractory PTCL.
